http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114836389-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-59 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-587 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-54346 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 |
| filingDate | 2022-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114836389-B |
| titleOfInvention | Hybridoma cell line secreting anti-HCG monoclonal antibody, anti-HCG monoclonal antibody and application |
| abstract | The present invention relates to the technical field of bioengineering, in particular to hybridoma cell lines secreting anti-HCG monoclonal antibodies, anti-HCG monoclonal antibodies and applications thereof, including hybridoma cell lines secreting anti-HCG monoclonal antibodies, including hybridoma cell lines C1 and The hybridoma cell line C2 was deposited in the China Center for Type Culture Collection; the hybridoma cell line C1 was deposited as CCTCC NO: C2021219, and the hybridoma line C2 was deposited as CCTCC NO: C2021220. After the monoclonal antibody secreted by the hybridoma cell line is treated with saturated ammonium sulfate and protein-A chromatography column, impurities can be effectively removed, and the monoclonal antibody with high purity, high titer, strong specificity and good stability can be obtained ; The monoclonal antibody obtained after purification is used for the production of detection reagent, which greatly improves the sensitivity of the reagent. |
| priorityDate | 2022-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.